Health Care • Biotechnology: Pharmaceutical Preparations
$593.54 ▲ +7.06
(+1.20%)
MKT CAP: $25.46B • VOL: 370.6K
52W L $430 52W H $610
UTHR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.18B | $2.88B | $2.33B |
| YoY Revenue Growth % | +10.6% | +23.6% | — |
| Gross Profit | $2.80B | $2.57B | $1.02B |
| Gross Margin % | 87.9% | 89.2% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.49B | $1.38B | $1.18B |
| Operating Margin % | 46.9% | 47.9% | 50.9% |
| Net Income (GAAP) | $1.33B | $1.20B | $984.8M |
| EBITDA (Normalized) | $1.91B | $1.57B | $1.27B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.56B | $1.33B | $978.0M |
| Capital Expenditures (CapEx) | $520.5M | $246.5M | $104.7M |
| Free Cash Flow (FCF) | $1.04B | $1.08B | $873.3M |
| FCF Margin % | 32.7% | 37.6% | 37.5% |
| Return on Invested Capital (ROIC %) | 20.0% | 21.1% | 11.1% |
| Cash & Short-Term Equivalents | $1.56B | $1.70B | $1.54B |
| Total Debt (Short + Long Term) | $352.7M | $414.0M | $3.28B |
| Total Stockholders' Equity | $7.10B | $6.44B | $6.72B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR UTHR.